Evidence map›Paper›PMID 38545118›Full record

Observational studyFrontiers in immunology2024

C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay.

Graciela Russomando, Diana Sanabria, Chyntia Carolina Díaz Acosta, Leticia Rojas, Laura Franco, Rossana Arenas, Giovanni Delogu, Mame Diarra Bousso Ndiaye, Rim Bayaa, Niaina Rakotosamimanana and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Graciela RussomandoInstituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Asunción, Paraguay.
Diana SanabriaInstituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Asunción, Paraguay.
Chyntia Carolina Díaz AcostaInstituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Asunción, Paraguay.
Leticia RojasInstituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Asunción, Paraguay.
Laura FrancoInstituto de Investigaciones en Ciencias de la Salud, National University of Asunción, Asunción, Paraguay.
Rossana ArenasHospital General de San Lorenzo, Ministerio de Salud Pública y Bienestar Social (MSPyBS), Asunción, Paraguay.
Giovanni DeloguDipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie - Sezione di Microbiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Mame Diarra Bousso NdiayeUnité des Mycobactéries, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Rim BayaaMedical and Scientific Department, Fondation Mérieux, Lyon, France.
Niaina RakotosamimananaUnité des Mycobactéries, Institut Pasteur de Madagascar, Antananarivo, Madagascar.
Delia GolettiTranslational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy.
Jonathan HoffmannMedical and Scientific Department, Fondation Mérieux, Lyon, France.
Universidad Nacional de Asunción · PYFondation Mérieux · FRInstitut Pasteur de Madagascar · MGIstituti di Ricovero e Cura a Carattere Scientifico · ITMinisterio de Salud Pública y Bienestar Social · PYUniversità Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: New diagnostic tools are needed to rapidly assess the efficacy of pulmonary tuberculosis (PTB) treatment. The aim of this study was to evaluate several immune biomarkers in an observational and cross-sectional cohort study conducted in Paraguay. Methods: Thirty-two patients with clinically and microbiologically confirmed PTB were evaluated before starting treatment (T0), after 2 months of treatment (T1) and at the end of treatment (T2). At each timepoint plasma levels of IFN-y, 17 pro- and anti-inflammatory cytokines/chemokines and complement factors C1q, C3 and C4 were assessed in unstimulated and Mtb-specific stimulated whole blood samples using QuantiFERON-TB gold plus and recombinant Results: In unstimulated plasma, C1q (P<0.001), C4 (P<0.001), hemoglobin (P<0.001), lymphocyte proportion (P<0.001) and absolute white blood cell count (P=0.01) were significantly higher in PTB patients at baseline than in cured patients. C1q and C4 levels were found to be related to Conclusion: This observational study provides new insights on host immune responses throughout anti-TB treatment and emphasizes the role of host C1q and HBHA-specific IL-13 response as surrogate plasma biomarkers for monitoring TB treatment efficacy.

Indexed as

TuberculosisTuberculosis, PulmonaryBiomarkersCohort StudiesComplement C1qCross-Sectional StudiesHumansInterleukin-13ParaguayBiomarkersComplement C1qInterleukin-13host biomarkersimmunodiagnosticplasma protein signaturepulmonary tuberculosistreatment immunomonitoring

Identifiers

PMID38545118
PMCPMC10967656
OpenAlexW4392740360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.